chr17-46938630-A-G
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The ENST00000640051.2(GOSR2):āc.509A>Gā(p.Asn170Ser) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000284 in 1,614,102 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ā ). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. N170K) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000640051.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GOSR2 | NM_004287.5 | c.509A>G | p.Asn170Ser | missense_variant | 6/6 | ENST00000640051.2 | NP_004278.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GOSR2 | ENST00000640051.2 | c.509A>G | p.Asn170Ser | missense_variant | 6/6 | 1 | NM_004287.5 | ENSP00000492751 | P3 |
Frequencies
GnomAD3 genomes AF: 0.000276 AC: 42AN: 152120Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000266 AC: 67AN: 251454Hom.: 0 AF XY: 0.000324 AC XY: 44AN XY: 135900
GnomAD4 exome AF: 0.000286 AC: 418AN: 1461864Hom.: 0 Cov.: 33 AF XY: 0.000287 AC XY: 209AN XY: 727240
GnomAD4 genome AF: 0.000269 AC: 41AN: 152238Hom.: 0 Cov.: 32 AF XY: 0.000296 AC XY: 22AN XY: 74420
ClinVar
Submissions by phenotype
not provided Uncertain:7
Uncertain significance, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Nov 01, 2020 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | May 28, 2023 | Reported in the heterozygous state in a patient with epilepsy, mild developmental delays and ADHD who also harbored a pathogenic variant in the SCN1A gene (de Lange et al., 2020); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 32032478) - |
Uncertain significance, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Jan 29, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jun 25, 2019 | - - |
Uncertain significance, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 17, 2022 | The c.509A>G (p.N170S) alteration is located in exon 6 (coding exon 6) of the GOSR2 gene. This alteration results from a A to G substitution at nucleotide position 509, causing the asparagine (N) at amino acid position 170 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Progressive myoclonic epilepsy type 6 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Feb 24, 2022 | - - |
Progressive myoclonic epilepsy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 12, 2022 | This sequence change replaces asparagine, which is neutral and polar, with serine, which is neutral and polar, at codon 170 of the GOSR2 protein (p.Asn170Ser). This variant is present in population databases (rs150907052, gnomAD 0.06%). This variant has not been reported in the literature in individuals affected with GOSR2-related conditions. ClinVar contains an entry for this variant (Variation ID: 205631). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at